Istodax (romidepsin)
Updated: Dec 8, 2009
| Brand Name: | Istodax |
| Generic Name: | romidepsin |
| Code Name: | depsipeptide |
| Company: | Celgene |
| FDA Clinical Phase: | 2 |
Description:
Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an enzyme known as histone deacetylase (HDAC). It alters the production of protein from DNA, inhibits the cell cycle, and causes cancer cells to die. Istodax, received FDA approval in November 2009 for the treatment of cutaneous T-cell lymphoma. Clinical trials studying the effects of Istodax and Velcade (bortezomib) in multiple myeloma are underway.
Clinical Trials:
For a list of clinical trials studying Istodax for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for Istodax: http://www.istodax.com/
Related Articles:
- Getting To Know: Tiragolumab
- Getting To Know: TNB-383B
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
